Market Assessment - Strategic assessment of injectable, in situ gelling materials for ocular drug delivery

市场评估 - 用于眼部药物输送的可注射原位胶凝材料的战略评估

基本信息

批准号：
556937-2020
负责人：
Sheardown, Heather
金额：
$ 1.09万
依托单位：
McMaster University
依托单位国家：
加拿大
项目类别：
Idea to Innovation
财政年份：
2020
资助国家：
加拿大
起止时间：
2020-01-01 至 2021-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=706389
关键词：
Market Assessment Strategic assessment injectable

项目摘要

Diseases in the eye are becoming increasingly common as the population ages; however, they remain notoriously difficult to treat. For instance, age-related macular degeneration (AMD) affects over 1.4 million Canadians and is the leading cause of vision loss in Canada. While the advent of anti-VEGF agents, a specific class of drugs, has significantly improved the prognosis and outcomes for many of these patients, they require intraocular injections every one to two months to maintain their effectiveness. Similarly, glaucoma, the second leading cause of blindness, requires patients to adhere to a challenging regime of eye drops multiple times each day, causing patients to struggle with compliance. Yet, if these conditions progress to vision loss, patients have been shown to require greater assistance with daily activities, suffer high incidences of depression and anxiety, and have twice the risk of falls; this all results in a substantial decrease in their quality of life. We propose a new delivery system that would work with different therapeutics for a variety of conditions. This would reduce treatments from monthly to bi-annually, increasing both safety and convenience for patients and reducing the burden on the healthcare system. We request funds to complete a Market Assessment to determine which ocular disease condition is best suited to initial development, which will allow us to then create a business plan for successful technology transfer and commercialization.

随着人口老龄化，眼部疾病变得越来越普遍。然而，众所周知，它们仍然难以治疗。例如，年龄相关性黄斑变性 (AMD) 影响超过 140 万加拿大人，是加拿大视力丧失的主要原因。虽然抗 VEGF 药物（一类特定药物）的出现显着改善了许多此类患者的预后和结果，但它们需要每隔一到两个月进行一次眼内注射才能维持其有效性。同样，青光眼是导致失明的第二大原因，需要患者每天多次坚持具有挑战性的滴眼药水方案，导致患者难以遵守规定。然而，如果这些情况发展为视力丧失，患者的日常活动需要更多帮助，抑郁和焦虑的发生率会很高，跌倒的风险也会增加一倍；这一切都导致他们的生活质量大幅下降。我们提出了一种新的输送系统，可以针对各种情况使用不同的疗法。这将使治疗次数从每月一次减少到每年两次，从而提高患者的安全性和便利性，并减轻医疗保健系统的负担。我们请求资金来完成市场评估，以确定哪种眼部疾病最适合初始开发，这将使我们能够制定成功的技术转让和商业化的商业计划。